February 23, 2024 New developments in cancer therapy include treatment with antibody-drug conjugates (ADCs), which are a targeted cancer therapy. Platinum-based chemotherapy is the primary treatment for patients with epithelial ovarian, fallopian, or primary peritoneal
January 23, 2024 Dr. Ben Gaddie wrote back in April about the anticipated FDA approval for Aldeyra’s Reproxalap. The PDUFA date was November 23, 2023, upon which Aldeyra would learn of the final review for
January 3, 2024 Christmas came early for me this year. On December 6, 2023, Dr. Jack Schaeffer called me at work. I tell my friends and family to not call me at work because that
September 1, 2023 It is the largest unmet market of all time. A condition that affects nearly 100% of all human beings. A scourge that maddens mankind to no end. Oceans are probably littered with
June 26, 2023 It’s hard to believe that our first therapeutic treatments for macular degeneration, Macugen/Avastin/Lucentis, were approved and hit the market between 2004 and 2006. While a great treatment for a condition for which
 May 25, 2023 Since at least 1915, when Cornell researchers William A. Riley and O.A. Johannsen first described the anatomy and classification of demodex mites, doctors and patients alike have been waiting for a treatment
April 11, 2023 After a relatively quiet pandemic-era paucity in new ophthalmic FDA approvals, 2023 may be the year that the pipeline first trickles then flows into the clinic. Our industry registered a near strike
April 11, 2023 I intentionally left off Aldeyra’s new agent Reproxalap when I reviewed many of the new FDA-approved drugs for 2023 because this agent required its own dedicated article. If you have been paying
April 11, 2023 Don’t all eye drops contain water? Until recently, that wasn’t even a question when considering the makeup of clinical topical preparations. Novaliq, a German company, has been quietly changing the very constructs
